Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease
The enzyme serum paraoxonase plays an important role in antioxidant defences and prevention of atherosclerosis. Metabolic syndrome (MS) is a clinical condition associated with increased oxidant stress and cardiovascular mortality. Two common polymorphisms of serum paraoxonase, PON1 Leu(55)Met and Gl...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental medicine 2005-05, Vol.5 (1), p.20-30 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | 1 |
| container_start_page | 20 |
| container_title | Clinical and experimental medicine |
| container_volume | 5 |
| creator | Martinelli, N Girelli, D Olivieri, O Cavallari, U Biscuola, M Trabetti, E Friso, S Pizzolo, F Tenuti, I Bozzini, C Villa, G Ceradini, B Sandri, M Cheng, S Grow, M A Pignatti, P F Corrocher, R |
| description | The enzyme serum paraoxonase plays an important role in antioxidant defences and prevention of atherosclerosis. Metabolic syndrome (MS) is a clinical condition associated with increased oxidant stress and cardiovascular mortality. Two common polymorphisms of serum paraoxonase, PON1 Leu(55)Met and Gln(192)Arg, have been postulated to modulate the cardiovascular risk. We studied 915 subjects with angiographic documentation: 642 subjects with coronary atherosclerosis and 273 with normal coronary arteries. Two hundred and twenty-four subjects met the diagnostic criteria of MS. We found a significant interaction between MS and both the PON1 polymorphisms in determining the risk of coronary artery disease (P |
| doi_str_mv | 10.1007/s10238-005-0060-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67890585</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>848708871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-ac41946ea97af92537c56ead7b1625bc5c0cdf0d6bee3a81af7faad46cee6ae63</originalsourceid><addsrcrecordid>eNpdkc1LNSEUhyWKvv-ANi_Sot2UOldHlxF9QVSLWssZPUPTO6M3nSHuf5-XeyEIFI_4nB_qQ8gZZ5ecseYqcyZqXTEmy1SsMjvkkEvDKyOF3t3WWht2QI5y_mSMS12zfXJQDoTWjTkk82OYMIGb-hhoi9M3YqAjTtDGoXc0r4JPcUQKwdPXl2dOl3FYjTEtP_o8ZgplUI8lYuwDhInGjk4fSFOf_69rF1MMkFYUUmFW1PcZIeMJ2etgyHi6XY_J-93t281D9fRy_3hz_VS5WqipArfgZqEQTAOdEbJunCw737RcCdk66ZjzHfOqRaxBc-iaDsAvlENUgKo-Jheb3GWKXzPmyY59djgMEDDO2aqmfI7UsoDnf8DPOKdQ7mZFzQomxDqNbyCXYs4JO7tM_VheZzmzayF2I8QWIXYtxJrS828bPLcj-t-OrYH6B7PfiRk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230678226</pqid></control><display><type>article</type><title>Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Martinelli, N ; Girelli, D ; Olivieri, O ; Cavallari, U ; Biscuola, M ; Trabetti, E ; Friso, S ; Pizzolo, F ; Tenuti, I ; Bozzini, C ; Villa, G ; Ceradini, B ; Sandri, M ; Cheng, S ; Grow, M A ; Pignatti, P F ; Corrocher, R</creator><creatorcontrib>Martinelli, N ; Girelli, D ; Olivieri, O ; Cavallari, U ; Biscuola, M ; Trabetti, E ; Friso, S ; Pizzolo, F ; Tenuti, I ; Bozzini, C ; Villa, G ; Ceradini, B ; Sandri, M ; Cheng, S ; Grow, M A ; Pignatti, P F ; Corrocher, R</creatorcontrib><description>The enzyme serum paraoxonase plays an important role in antioxidant defences and prevention of atherosclerosis. Metabolic syndrome (MS) is a clinical condition associated with increased oxidant stress and cardiovascular mortality. Two common polymorphisms of serum paraoxonase, PON1 Leu(55)Met and Gln(192)Arg, have been postulated to modulate the cardiovascular risk. We studied 915 subjects with angiographic documentation: 642 subjects with coronary atherosclerosis and 273 with normal coronary arteries. Two hundred and twenty-four subjects met the diagnostic criteria of MS. We found a significant interaction between MS and both the PON1 polymorphisms in determining the risk of coronary artery disease (P<0.05 by likelihood-ratio test). The 55Leu and the 192Arg alleles, associated with reduced protection against lipid peroxidation, were associated with coronary artery disease only in the MS subgroup. Subjects with MS and both 55Leu and 192Arg alleles had significantly increased risk (OR=9.38 with 95% CI=3.02-29.13 after adjustment by multiple logistic regression) as compared to subjects without MS and with 55Met/Met-192Gln/Gln genotype. No increased risk was found for subjects with MS and the 55Met/Met-192Gln/Gln genotype. This study highlights a potential example of genetic (paraoxonase polymorphisms)-clinical (MS) interaction influencing cardiovascular risk.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-005-0060-9</identifier><identifier>PMID: 15928879</identifier><identifier>CODEN: CEMLBA</identifier><language>eng</language><publisher>Italy: Springer Nature B.V</publisher><subject>Aged ; Aryldialkylphosphatase - genetics ; Cardiovascular disease ; Coronary Artery Disease - complications ; Coronary Artery Disease - enzymology ; Coronary Artery Disease - genetics ; Enzymes ; Female ; Humans ; Male ; Metabolic Syndrome - complications ; Metabolic Syndrome - enzymology ; Metabolic Syndrome - genetics ; Metabolism ; Middle Aged ; Polymorphism ; Polymorphism, Genetic ; Risk Factors</subject><ispartof>Clinical and experimental medicine, 2005-05, Vol.5 (1), p.20-30</ispartof><rights>Springer-Verlag Italia 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-ac41946ea97af92537c56ead7b1625bc5c0cdf0d6bee3a81af7faad46cee6ae63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15928879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martinelli, N</creatorcontrib><creatorcontrib>Girelli, D</creatorcontrib><creatorcontrib>Olivieri, O</creatorcontrib><creatorcontrib>Cavallari, U</creatorcontrib><creatorcontrib>Biscuola, M</creatorcontrib><creatorcontrib>Trabetti, E</creatorcontrib><creatorcontrib>Friso, S</creatorcontrib><creatorcontrib>Pizzolo, F</creatorcontrib><creatorcontrib>Tenuti, I</creatorcontrib><creatorcontrib>Bozzini, C</creatorcontrib><creatorcontrib>Villa, G</creatorcontrib><creatorcontrib>Ceradini, B</creatorcontrib><creatorcontrib>Sandri, M</creatorcontrib><creatorcontrib>Cheng, S</creatorcontrib><creatorcontrib>Grow, M A</creatorcontrib><creatorcontrib>Pignatti, P F</creatorcontrib><creatorcontrib>Corrocher, R</creatorcontrib><title>Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><description>The enzyme serum paraoxonase plays an important role in antioxidant defences and prevention of atherosclerosis. Metabolic syndrome (MS) is a clinical condition associated with increased oxidant stress and cardiovascular mortality. Two common polymorphisms of serum paraoxonase, PON1 Leu(55)Met and Gln(192)Arg, have been postulated to modulate the cardiovascular risk. We studied 915 subjects with angiographic documentation: 642 subjects with coronary atherosclerosis and 273 with normal coronary arteries. Two hundred and twenty-four subjects met the diagnostic criteria of MS. We found a significant interaction between MS and both the PON1 polymorphisms in determining the risk of coronary artery disease (P<0.05 by likelihood-ratio test). The 55Leu and the 192Arg alleles, associated with reduced protection against lipid peroxidation, were associated with coronary artery disease only in the MS subgroup. Subjects with MS and both 55Leu and 192Arg alleles had significantly increased risk (OR=9.38 with 95% CI=3.02-29.13 after adjustment by multiple logistic regression) as compared to subjects without MS and with 55Met/Met-192Gln/Gln genotype. No increased risk was found for subjects with MS and the 55Met/Met-192Gln/Gln genotype. This study highlights a potential example of genetic (paraoxonase polymorphisms)-clinical (MS) interaction influencing cardiovascular risk.</description><subject>Aged</subject><subject>Aryldialkylphosphatase - genetics</subject><subject>Cardiovascular disease</subject><subject>Coronary Artery Disease - complications</subject><subject>Coronary Artery Disease - enzymology</subject><subject>Coronary Artery Disease - genetics</subject><subject>Enzymes</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Metabolic Syndrome - complications</subject><subject>Metabolic Syndrome - enzymology</subject><subject>Metabolic Syndrome - genetics</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Polymorphism</subject><subject>Polymorphism, Genetic</subject><subject>Risk Factors</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1LNSEUhyWKvv-ANi_Sot2UOldHlxF9QVSLWssZPUPTO6M3nSHuf5-XeyEIFI_4nB_qQ8gZZ5ecseYqcyZqXTEmy1SsMjvkkEvDKyOF3t3WWht2QI5y_mSMS12zfXJQDoTWjTkk82OYMIGb-hhoi9M3YqAjTtDGoXc0r4JPcUQKwdPXl2dOl3FYjTEtP_o8ZgplUI8lYuwDhInGjk4fSFOf_69rF1MMkFYUUmFW1PcZIeMJ2etgyHi6XY_J-93t281D9fRy_3hz_VS5WqipArfgZqEQTAOdEbJunCw737RcCdk66ZjzHfOqRaxBc-iaDsAvlENUgKo-Jheb3GWKXzPmyY59djgMEDDO2aqmfI7UsoDnf8DPOKdQ7mZFzQomxDqNbyCXYs4JO7tM_VheZzmzayF2I8QWIXYtxJrS828bPLcj-t-OrYH6B7PfiRk</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Martinelli, N</creator><creator>Girelli, D</creator><creator>Olivieri, O</creator><creator>Cavallari, U</creator><creator>Biscuola, M</creator><creator>Trabetti, E</creator><creator>Friso, S</creator><creator>Pizzolo, F</creator><creator>Tenuti, I</creator><creator>Bozzini, C</creator><creator>Villa, G</creator><creator>Ceradini, B</creator><creator>Sandri, M</creator><creator>Cheng, S</creator><creator>Grow, M A</creator><creator>Pignatti, P F</creator><creator>Corrocher, R</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease</title><author>Martinelli, N ; Girelli, D ; Olivieri, O ; Cavallari, U ; Biscuola, M ; Trabetti, E ; Friso, S ; Pizzolo, F ; Tenuti, I ; Bozzini, C ; Villa, G ; Ceradini, B ; Sandri, M ; Cheng, S ; Grow, M A ; Pignatti, P F ; Corrocher, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-ac41946ea97af92537c56ead7b1625bc5c0cdf0d6bee3a81af7faad46cee6ae63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Aryldialkylphosphatase - genetics</topic><topic>Cardiovascular disease</topic><topic>Coronary Artery Disease - complications</topic><topic>Coronary Artery Disease - enzymology</topic><topic>Coronary Artery Disease - genetics</topic><topic>Enzymes</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Metabolic Syndrome - complications</topic><topic>Metabolic Syndrome - enzymology</topic><topic>Metabolic Syndrome - genetics</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Polymorphism</topic><topic>Polymorphism, Genetic</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martinelli, N</creatorcontrib><creatorcontrib>Girelli, D</creatorcontrib><creatorcontrib>Olivieri, O</creatorcontrib><creatorcontrib>Cavallari, U</creatorcontrib><creatorcontrib>Biscuola, M</creatorcontrib><creatorcontrib>Trabetti, E</creatorcontrib><creatorcontrib>Friso, S</creatorcontrib><creatorcontrib>Pizzolo, F</creatorcontrib><creatorcontrib>Tenuti, I</creatorcontrib><creatorcontrib>Bozzini, C</creatorcontrib><creatorcontrib>Villa, G</creatorcontrib><creatorcontrib>Ceradini, B</creatorcontrib><creatorcontrib>Sandri, M</creatorcontrib><creatorcontrib>Cheng, S</creatorcontrib><creatorcontrib>Grow, M A</creatorcontrib><creatorcontrib>Pignatti, P F</creatorcontrib><creatorcontrib>Corrocher, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martinelli, N</au><au>Girelli, D</au><au>Olivieri, O</au><au>Cavallari, U</au><au>Biscuola, M</au><au>Trabetti, E</au><au>Friso, S</au><au>Pizzolo, F</au><au>Tenuti, I</au><au>Bozzini, C</au><au>Villa, G</au><au>Ceradini, B</au><au>Sandri, M</au><au>Cheng, S</au><au>Grow, M A</au><au>Pignatti, P F</au><au>Corrocher, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease</atitle><jtitle>Clinical and experimental medicine</jtitle><addtitle>Clin Exp Med</addtitle><date>2005-05</date><risdate>2005</risdate><volume>5</volume><issue>1</issue><spage>20</spage><epage>30</epage><pages>20-30</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><coden>CEMLBA</coden><abstract>The enzyme serum paraoxonase plays an important role in antioxidant defences and prevention of atherosclerosis. Metabolic syndrome (MS) is a clinical condition associated with increased oxidant stress and cardiovascular mortality. Two common polymorphisms of serum paraoxonase, PON1 Leu(55)Met and Gln(192)Arg, have been postulated to modulate the cardiovascular risk. We studied 915 subjects with angiographic documentation: 642 subjects with coronary atherosclerosis and 273 with normal coronary arteries. Two hundred and twenty-four subjects met the diagnostic criteria of MS. We found a significant interaction between MS and both the PON1 polymorphisms in determining the risk of coronary artery disease (P<0.05 by likelihood-ratio test). The 55Leu and the 192Arg alleles, associated with reduced protection against lipid peroxidation, were associated with coronary artery disease only in the MS subgroup. Subjects with MS and both 55Leu and 192Arg alleles had significantly increased risk (OR=9.38 with 95% CI=3.02-29.13 after adjustment by multiple logistic regression) as compared to subjects without MS and with 55Met/Met-192Gln/Gln genotype. No increased risk was found for subjects with MS and the 55Met/Met-192Gln/Gln genotype. This study highlights a potential example of genetic (paraoxonase polymorphisms)-clinical (MS) interaction influencing cardiovascular risk.</abstract><cop>Italy</cop><pub>Springer Nature B.V</pub><pmid>15928879</pmid><doi>10.1007/s10238-005-0060-9</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-8890 |
| ispartof | Clinical and experimental medicine, 2005-05, Vol.5 (1), p.20-30 |
| issn | 1591-8890 1591-9528 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67890585 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Aryldialkylphosphatase - genetics Cardiovascular disease Coronary Artery Disease - complications Coronary Artery Disease - enzymology Coronary Artery Disease - genetics Enzymes Female Humans Male Metabolic Syndrome - complications Metabolic Syndrome - enzymology Metabolic Syndrome - genetics Metabolism Middle Aged Polymorphism Polymorphism, Genetic Risk Factors |
| title | Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T12%3A24%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interaction%20between%20metabolic%20syndrome%20and%20PON1%20polymorphisms%20as%20a%20determinant%20of%20the%20risk%20of%20coronary%20artery%20disease&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Martinelli,%20N&rft.date=2005-05&rft.volume=5&rft.issue=1&rft.spage=20&rft.epage=30&rft.pages=20-30&rft.issn=1591-8890&rft.eissn=1591-9528&rft.coden=CEMLBA&rft_id=info:doi/10.1007/s10238-005-0060-9&rft_dat=%3Cproquest_cross%3E848708871%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230678226&rft_id=info:pmid/15928879&rfr_iscdi=true |